Table 1.
Ongoing CAR therapy trials in AML.
| Target Antigen | Name of Drug | CAR Cell Type | Phase | https://clinicaltrials.gov/ (accessed on 21 December 2021) ID | Age (years) | Country |
|---|---|---|---|---|---|---|
| CD7 | CD7 CAR-T | T | I/II | NCT04762485 | 12 to 65 | China |
| CD7 | CD7 CAR-T | T | I/II | NCT04033302 | Up to 75 | China |
| CD19 | CAR-T CD19 | T | II/III | NCT04257175 | 18 and up | Israel |
| CD33 | CD33 CAR-T | T | I/II | NCT04835519 | 1 to 70 | China |
| CD33 | CD33CART | T | I/II | NCT03971799 | 1 to 35 | USA |
| CD33 | CART-33 | T | I | NCT02799680 | 50 and up | China |
| CD33 | PRGN-3006 | T | I | NCT03927261 | 18 and up | USA |
| CD33/CLL1 | Dual CD33-CLL1 CAR-T | T | I | NCT05016063 | 18 to 70 | China |
| CD38 | CART-38 | T | I/II | NCT04351022 | 6 to 65 | China |
| CD44v6 | CD44v6 CAR-T | T | I/II | NCT04097301 | 1 to 75 | Italy |
| CD70 | CD70 CAR-T | T | I | NCT04662294 | All | China |
| CD70 | CAR.70/IL-15 | NK | I/II | NCT05092451 | 18 and up | USA |
| CD123 | IM23 CAR-T | T | I | NCT03585517 | 3 to 80 | China |
| CD123 | IL-3 CAR-T | T | I | NCT04599543 | All | China |
| CD123 | Anti-CD123 CAR-T | T | I | NCT04014881 | 18 to 70 | China |
| CD123 | CD123-CAR-T | T | I | NCT04318678 | Up to 21 | USA |
| CD123 | CART-123 | T | I/II | NCT03556982 | 14 to 75 | China |
| CD123 | CD123 CAR-T | T | I/II | NCT04272125 | 3 to 75 | China |
| CD123 | CD123 CAR-T | T | I/II | NCT04265963 | 2 to 75 | China |
| CD123 | UCART123v1.2 | T | I | NCT03190278 | 18 to 65 | USA |
| CD123 | UniCAR02-T | T | I | NCT04230265 | 18 and up | Germany |
| CD123 | CD123-CAR-CD28-CD3z-EGFRt | T | I | NCT02159495 | 12 and up | USA |
| CD123 | CART123 | T | I | NCT04678336 | 1 to 29 | USA |
| CD123 | CART123 | T | I | NCT03766126 | 18 and up | USA |
| CD123/CLL-1 | CD123/CLL1 CAR-T | T | II/III | NCT03631576 | Up to 70 | China |
| CD276 | TAA6 | T | I | NCT04692948 | 18 to 70 | China |
| CLL-1 | CLL-1 CAR-T | T | I | NCT04219163 | Up to 75 | USA |
| CLL-1 | KITE-222 | T | I | NCT04789408 | 18 and up | USA |
| CLL1 | Anti-CLL1 CART | T | I/II | NCT04884984 | 6 to 65 | China |
| CLL1 | Anti-CLL1 CART | T | I | NCT04923919 | 2 to 75 | China |
| FLT3 | Anti-FLT3 CAR-T | T | I/II | NCT05023707 | 16 to 65 | China |
| FLT3 | AMG553 | T | I | NCT03904069 | 12 and up | USA |
| FLT3 | TAA05 | T | NCT05017883 | 18 to 70 | China | |
| ILT3 | Anti-ILT3 CAR-T | T | I | NCT04803929 | 18 to 70 | China |
| NKG2D | CYAD-02 | NK | I | NCT04167696 | 18 and up | USA |
| NKG2D | NKX101 | NK | I | NCT04623944 | 18 and up | USA |
| NKG2D | NKG2D CAR-T | NK | I | NCT04658004 | 3 to 70 | China |
CAR = chimeric antigen receptor; AML = acute myeloid leukemia; CD = cluster of differentiation; CLL-1 = C-type lectin-like molecule-1; FLT3 = FMS related receptor tyrosine kinase 3; ILT3 = Ig-like transcript 3; NKG2D = natural killer group 2 member D.